Rui Kitadai

Switching administration of <scp>anti‐PD</scp>‐1 and <scp>anti‐PD‐L1</scp> antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review

Shingo Kitagawa, Taiki Hakozaki, Rui Kitadai et al. · Thoracic Cancer · 2020 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Antoine Desîlets, Félix Blanc‐Durand, Sally C. M. Lau et al. · European Journal of Cancer · 2020 · 78 citations

Medicine, Oncology, Radiation Oncology +14

The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases

Rui Kitadai, Yusuke Okuma, Taiki Hakozaki et al. · Journal of Cancer Research and Clinical Oncology · 2019 · 52 citations · Full text

Medicine, Immunology, Oncology +16

Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

Taiki Hakozaki, Yukio Hosomi, Akihiro Shimizu et al. · Journal of Cancer Research and Clinical Oncology · 2020 · 32 citations · Full text

Medicine, Oncology, Pharmacology +17

Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients

Akihiro Yoshimura, Tadaaki Yamada, Yusuke Okuma et al. · Translational Lung Cancer Research · 2019 · 31 citations · Full text

Medicine, Oncology, Pharmacotherapy +17